

Form PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. LIT-PI-529D1		SERIAL NO. <u>618560</u> Filed Herewith	
LIST OF ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT William K. Koener		FILING DATE Filed Herewith	
				GROUP Unknown		<u>1648</u>	
U.S. PATENT DOCUMENTS							
*Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate	
AA	5591829	01/07/97	Matsushita	530	391.1		
	5633388	05/27/97	Diana et al	514	393		
	5645836	07/08/97	Kitto	424	159.1		
	5677274	10/14/97	Leppla et al	514	2		
	5684024	11/04/97	Diana et al	548	365.4		
	5767072	06/16/98	Vietta et al	424	194.1		
	5821243	10/13/98	Diana et al	544	238		
	5830894	11/03/98	Pevear et al	514	243		
	5834599	11/10/98	Chang et al	530	388.35		
	5935957	8/10/99	Diana et al	514	247		
	6333303	12/25/01	Borgford	514	2		
FOREIGN PATENT DOCUMENTS							
	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
AL	WO97/41233	11/6/97	PCT				
OTHER REFERENCES (including Author, Title, Date, Pertinent Pages, Etc.)							
AR		Lord, J.M., et al, "Ricin: Structure, Mode of Action, and Some Current Applications", <u>The FASEB Journal</u> , Vol.8 pp. 201and 206, 2/94.					
		Richardson, P.T. et al, "Recombinant Proricin Binds Galactose But Does Not Depurinate 28 S Ribosomal RNA," <u>FEBS 07564</u> , Vol 255, No. 1, page 15, 9/89.					
AS		Westby, M.W., et al, "Preparation and Characterization of Recombinant, Proricin Containing an Alternative Protease-Sensitive Linker Sequence," <u>Bioconjugate Chemistry</u> , 1992, 3, p. 375.					
		Darket, P.L., et al., "Human Immunodeficiency Virus Protease," <u>Journal of Biological Chemistry</u> , Vol 264, No. 4, p. 2307 1989.					
AT		Jordan, S.P., et al, "Activity and Dimerization of Human Immunodeficiency Virus Protease as a Function of Solvent Composition and Enzyme Concentration," <u>Journal of Biological Chemistry</u> , Vol. 267, No. 28, p. 20028. 1992.					
		Van Quen, M.G., "Rationale for the Use of Immunotoxins in the Treatment of HIV-Infected Humans," <u>Journal of Drug Targeting</u> , Vol 5, No. 2 p. 75, 1997.					
EXAMINER				DATE CONSIDERED			
3/16/05							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. LIT-PI-529	SERIAL NO. Filed Herewith				
LIST OF ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT William K. Keener, et al					
				FILING DATE Filed Herewith	GROUP Unknown				
U.S. PATENT DOCUMENTS									
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate		
	AA	/							
	AB								
	AC								
	AD								
	AE								
	AF								
	AG								
	AH								
	AI								
	AJ								
	AK								
FOREIGN PATENT DOCUMENTS									
		Document Number	Date	Country	Class	Subclass	Translation		
	AL	/					Yes	No	
	AM								
	AN								
	AO								
	AP								
OTHER REFERENCES (including Author, Title, Date, Pertinent Pages, Etc.)									
/	AR		Wachinger, M., et al, "Bryodin, a Single-Chain Ribosome-Inactivating Protein, Selectively Inhibits the Growth of HIV-1-Infected Cells and Reduces HIV-1 Production," <u>Research in Experimental Medicine</u> , 193:1-2, 1993.						
			Till, M.A., et al, "HIV-Infected Cells are Killed by rCF4-Ricin A Chain," <u>Science</u> , Vol. 24 p. 1166.						
/	AS	/							
/	AT	/							
EXAMINER				DATE CONSIDERED					
						3/16/05			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									